IL234262A - Pharmaceuticals containing ccr3 inhibitors - Google Patents
Pharmaceuticals containing ccr3 inhibitorsInfo
- Publication number
- IL234262A IL234262A IL234262A IL23426214A IL234262A IL 234262 A IL234262 A IL 234262A IL 234262 A IL234262 A IL 234262A IL 23426214 A IL23426214 A IL 23426214A IL 234262 A IL234262 A IL 234262A
- Authority
- IL
- Israel
- Prior art keywords
- eosinophilic
- formula
- alkyl
- nasal
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL234262A true IL234262A (en) | 2017-10-31 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL234262A IL234262A (en) | 2012-04-03 | 2014-08-24 | Pharmaceuticals containing ccr3 inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (enExample) |
| EP (3) | EP4389217A3 (enExample) |
| JP (2) | JP2015512432A (enExample) |
| KR (5) | KR20210063481A (enExample) |
| CN (2) | CN104220073A (enExample) |
| AU (1) | AU2013245027B2 (enExample) |
| BR (1) | BR112014023795B1 (enExample) |
| CA (1) | CA2869269C (enExample) |
| CL (1) | CL2014002523A1 (enExample) |
| CY (1) | CY1123222T1 (enExample) |
| DK (1) | DK2833884T3 (enExample) |
| EA (1) | EA032263B1 (enExample) |
| ES (2) | ES2987267T3 (enExample) |
| HR (1) | HRP20201165T1 (enExample) |
| HU (1) | HUE051648T2 (enExample) |
| IL (1) | IL234262A (enExample) |
| IN (1) | IN2014DN06989A (enExample) |
| LT (1) | LT2833884T (enExample) |
| MX (1) | MX2014011786A (enExample) |
| NZ (1) | NZ628882A (enExample) |
| PH (1) | PH12014502239A1 (enExample) |
| PL (1) | PL2833884T3 (enExample) |
| PT (1) | PT2833884T (enExample) |
| RS (1) | RS60665B1 (enExample) |
| SI (1) | SI2833884T1 (enExample) |
| SM (1) | SMT202000499T1 (enExample) |
| WO (1) | WO2013149986A1 (enExample) |
| ZA (1) | ZA201406082B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11045284B2 (en) | 2016-11-24 | 2021-06-29 | Kirishima Seiko Co., Ltd. | Dental brace and method for attaching dental brace |
| NZ757769A (en) * | 2017-04-05 | 2025-10-31 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| WO2018187503A1 (en) | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
| AU2019271122A1 (en) | 2018-05-15 | 2020-11-12 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| CA3111433A1 (en) * | 2018-09-26 | 2020-04-02 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| JP2023529719A (ja) * | 2020-06-11 | 2023-07-11 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患の転帰改善方法 |
| US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL151499A0 (en) * | 2000-03-03 | 2003-04-10 | Cambridge Antibody Tech | Human antibodies against eotaxin and their use |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8778616B2 (en) * | 2009-05-26 | 2014-07-15 | University Of Kentucky Research Foundation | Method of using CCR3 binding agents to detect choroidal neovascularization |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234262A (en) | Pharmaceuticals containing ccr3 inhibitors | |
| AU2009210655B2 (en) | Treatment of bladder diseases with a TLR7 activator | |
| JP2009007337A (ja) | 加齢黄斑変性の予防又は治療剤 | |
| KR20160065979A (ko) | 안질환의 치료제 또는 예방제 | |
| PT1558254E (pt) | Utilização de compostos de 4-aminoquinolinas para o tratamento de doenças inflamatórias dos olhos | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2022504184A (ja) | ブドウ膜黒色腫の治療のための併用療法 | |
| WO2009019473A1 (en) | Treatments for inflammatory arthritis | |
| CN105163732B (zh) | 用于治疗眼科疾病和病症的方法 | |
| CN101677998B (zh) | 包含西洛他唑的治疗精神分裂症药物 | |
| WO2014034756A1 (ja) | けいれん重積発作の治療用医薬組成物 | |
| TW202140470A (zh) | 使用Bcl-2 抑制劑之癌症治療方法 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| JP4853837B2 (ja) | 過敏性腸症候群治療剤 | |
| JP2009235069A (ja) | ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤 | |
| JPWO2007100079A1 (ja) | 三環性トリアゾロベンゾアゼピン誘導体を含有する、アレルギー性眼疾患またはアレルギー性鼻疾患の予防または治療剤 | |
| KR20190054549A (ko) | 말초신경의 나트륨-채널병증을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 | |
| WO2025135087A1 (ja) | 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物 | |
| JP2024510249A (ja) | 神経疾患を治療するための組成物およびその方法 | |
| WO2007010946A1 (ja) | 滑膜細胞増殖抑制剤 | |
| CN109758453A (zh) | 胺类化合物治疗焦虑障碍的医药用途 | |
| KR20140097485A (ko) | 망막 보호용의 7-(1h-이미다졸-4-일메틸)-5,6,7,8-테트라하이드로-퀴놀린을 포함하는 약제학적 조성물 | |
| WO2012110946A1 (en) | Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate | |
| WO2000061148A1 (en) | Inhibitors for optic hypofunction caused by optic nerve cell injury induced by factors other than optic circulatory disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |